Progressive Multifocal Leukoencephalopathy

This is a serious brain infection caused by a virus called JC virus. It affects the white matter of the brain, causing symptoms like confusion, trouble walking, vision problems, and loss of speech. It usually happens in people with weakened immune systems.

Condition

What people with Progressive Multifocal Leukoencephalopathy report

Every report comes from a Lived member, sent anonymously.

Have you tried Highly Active Antiretroviral Therapy for Progressive Multifocal Leukoencephalopathy?

NameHow it went

About Progressive Multifocal Leukoencephalopathy

What It Is

Progressive multifocal leukoencephalopathy (PML) is a rare and serious brain infection caused by the JC virus. The virus damages the cells that make myelin, the fatty insulation around nerve fibers, so patches of the brain's white matter stop carrying signals properly. The name describes the disease: it keeps getting worse (progressive), it affects several areas at once (multifocal), and it damages white matter (leukoencephalopathy). PML happens almost only in people whose immune system is weakened. Symptoms depend on which parts of the brain are affected and usually build over several weeks to months. Common early problems include clumsiness, weakness that gradually spreads or deepens, trouble with speech or vision, and changes in thinking or personality. Seizures can also occur. Because these symptoms can look like a stroke, a brain tumor or a flare of multiple sclerosis, PML is often missed at first, and that delay matters because outcomes are better when it is recognized early.

Causes & Risk Factors

Most adults already carry the JC virus. It is usually picked up in childhood, causes no symptoms, and stays quietly in the body for life. PML develops when the immune system can no longer keep the virus in check, allowing it to change into a form that can reach and infect the brain. Having the virus is common; having PML is rare. HIV is the most common underlying cause, especially when it is untreated or advanced, although PML can occur in people with HIV whose immune cell counts are not very low. Other settings include blood cancers such as lymphoma and leukemia, organ or stem cell transplants, inherited or unexplained immune deficiencies, and autoimmune diseases such as lupus and sarcoidosis. Certain medicines that weaken or redirect the immune system also raise the risk. The best known is natalizumab (Tysabri), an infusion used for multiple sclerosis and Crohn's disease. With natalizumab, risk is higher in people who have antibodies to the JC virus on a blood test, who have received it for more than two years, or who previously took other immune-suppressing drugs. A smaller risk has been reported with some other multiple sclerosis treatments, rituximab (Rituxan), an antibody infusion used for some lymphomas and leukemias and for autoimmune diseases such as rheumatoid arthritis, and certain cancer and transplant medicines. For people taking these drugs, the risk depends heavily on the specific medicine and personal factors, which is why it is discussed when treatment is chosen.

How It's Diagnosed

PML is suspected when someone with a weakened immune system develops neurological symptoms that steadily worsen over days to weeks. A clinician reviews the medical history in detail, including medicines taken over the past couple of years, to identify a reason the immune system may be impaired. MRI (magnetic resonance imaging) of the brain is the key imaging test. PML usually appears as patches of damaged white matter with a pattern that helps distinguish it from stroke, tumors and multiple sclerosis lesions. A spinal tap (lumbar puncture) collects cerebrospinal fluid, the fluid around the brain and spinal cord, to look for JC virus genetic material. Finding the virus in the spinal fluid along with typical symptoms and MRI findings confirms the diagnosis. Current tests detect the virus in most cases, but a negative result does not fully rule PML out, so the test may be repeated. When the diagnosis remains uncertain, a small brain biopsy may be needed. A blood test for JC virus antibodies does not diagnose PML, because more than half of adults have these antibodies. It is mainly used to estimate risk before and during natalizumab treatment.

Treatment Options

There is no antiviral medicine proven to stop the JC virus. Treatment centers on restoring the immune system so the body can control the infection itself, and the approach depends on why the immune system was weakened. For people with HIV, that means starting or optimizing antiretroviral therapy (ART), the combination of medicines that suppresses HIV and allows immune cells to recover. For drug-associated PML, the medicine responsible is stopped, and other immune-suppressing treatments are reduced where possible. For people with a transplant, lowering immune-suppressing medicine has to be weighed against the risk of rejection. As immunity recovers, some people develop immune reconstitution inflammatory syndrome (IRIS), in which the returning immune response attacks infected brain areas and symptoms temporarily worsen. This can happen weeks to months after ART starts or a drug is stopped. When immunity cannot be restored, specialists may consider experimental approaches, such as pembrolizumab (Keytruda), an immune checkpoint inhibitor that helps the immune system fight infections and cancer, or lab-grown immune cells targeted against the virus. Evidence for these comes only from small case series. Some people have improved or stabilized, but none of these treatments is approved for PML.

What to Expect

PML is a serious illness, and the outlook depends largely on whether the immune system can recover. Overall, about 30 to 50 percent of people die in the first few months after diagnosis. Death rates vary widely with the underlying cause: they are lower in HIV-associated PML treated with ART and higher when PML occurs with blood cancers or ongoing heavy immune suppression. For those who survive, the infection often stops progressing once immunity returns, but brain damage that has already happened usually does not fully reverse. Many people live with lasting weakness, coordination or vision problems, or changes in thinking, and some need help with daily activities. The early months often involve hospital care, rehabilitation and a period of uncertainty while the team watches for improvement or IRIS. Follow-up includes repeat neurological exams and MRI scans, close management of the underlying condition (such as HIV viral load and immune cell counts, which show whether HIV is suppressed and the immune system is recovering), and planning for home support, driving and work as abilities become clearer.

When to Seek Help

If you have HIV, a blood cancer, a transplant or take immune-suppressing medicine, ask your care team at a routine visit about your PML risk and what symptoms to watch for, especially before starting or continuing a treatment known to carry this risk. Contact your care team right away about new neurological problems that keep worsening over several days, such as clumsiness, weakness on one side, trouble speaking, changes in vision, or new confusion or memory problems. If you receive natalizumab (Tysabri), do this during treatment and for six months after the last dose. A seizure, or weakness, numbness or loss of speech that comes on suddenly, needs emergency care rather than a call to the team. If you are already being treated for PML and symptoms worsen after starting ART or stopping a medicine, tell your team promptly, since this may be IRIS and needs assessment.

Questions to Ask Your Doctor

  1. 1.What is weakening my immune system, and how quickly can it be restored?
  2. 2.Is the diagnosis confirmed, and do any tests need to be repeated?
  3. 3.What signs would suggest IRIS, and how would it be treated?
  4. 4.Are there clinical trials or experimental treatments that make sense in my situation?
  5. 5.What rehabilitation and home support should we plan for now?

Last reviewed • Oct 2026

Educational content, not medical advice.